
Opinion|Videos|April 4, 2025
Public Perceptions of Patients With Alopecia Areata
Author(s)Arash Mostaghimi, MD, MPH, Brett King, MD, PhD
A panelist discusses how dermatologists typically see patients with alopecia areata after they've already experienced significant hair loss and undergone initial treatments with primary care providers, which impacts treatment by creating potential delays in optimal intervention, heightened patient anxiety, and the need for more aggressive therapeutic approaches to address established disease patterns.
Advertisement
Episodes in this series

At what point in a patient’s journey do dermatologists typically see patients, and how does this impact treatment?
Advertisement
Related to this article

The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.

Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.

Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.

Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.

IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Advertisement
Advertisement
Trending on HCPLive
1
Cardiac Health Indicators Improve Following CCM Implantation in Heart Failure
2
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
3
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
4
HCPLive Five at CHEST 2026
5

